<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD08590000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P06401</UniProt_ID>
  <Seq_Length>933</Seq_Length>
  <Molecule_Weight>98981</Molecule_Weight>
  <KEGG_ID>hsa:5241</KEGG_ID>
  <Orthology_ID>K08556</Orthology_ID>
  <EBI_ID>EBI-78539</EBI_ID>
  <Function_Summary>The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Progesterone receptor isoform B (PRB) is involved activation of c-SRC/MAPK signaling on hormone stimulation.Isoform A is inactive in stimulating c-Src/MAPK signaling on hormone stimulation.</Function_Summary>
  <Pfam_ID>PF00104:Hormone_recep@@PF02161:Prog_receptor@@PF00105:zf-C4</Pfam_ID>
  <Allosteric_Activator_Count>1</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>2</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>9</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>Nuclear receptor subfamily 3 group C member 3</Alias>
      <Alias>PR</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with zinc (Zn) ions.</Detail>
      <Keyword>Zinc ion binding</Keyword>
      <Ontology_ID>GO:0008270</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a steroid, any of a large group of substances that have in common a ring system based on 1,2-cyclopentanoperhydrophenanthrene.</Detail>
      <Keyword>Steroid binding</Keyword>
      <Ontology_ID>GO:0005496</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a lipid.</Detail>
      <Keyword>Lipid binding</Keyword>
      <Ontology_ID>GO:0008289</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with an extracellular or intracellular messenger to initiate a change in cell activity.</Detail>
      <Keyword>Receptor activity</Keyword>
      <Ontology_ID>GO:0004872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with a steroid hormone to initiate a change in cell activity.</Detail>
      <Keyword>Steroid hormone receptor activity</Keyword>
      <Ontology_ID>GO:0003707</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with one or more specific sites on a receptor molecule, a macromolecule that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function.</Detail>
      <Keyword>Receptor binding</Keyword>
      <Ontology_ID>GO:0005102</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any enzyme.</Detail>
      <Keyword>Enzyme binding</Keyword>
      <Ontology_ID>GO:0019899</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with DNA of a specific nucleotide composition, e.g. GC-rich DNA binding, or with a specific sequence motif or type of DNA e.g. promotor binding or rDNA binding.</Detail>
      <Keyword>Sequence-specific DNA binding</Keyword>
      <Ontology_ID>GO:0043565</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any metal ion.</Detail>
      <Keyword>Metal ion binding</Keyword>
      <Ontology_ID>GO:0046872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Any molecular function by which a gene product interacts selectively with DNA (deoxyribonucleic acid).</Detail>
      <Keyword>DNA binding</Keyword>
      <Ontology_ID>GO:0003677</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>301</Position>
      <Original>Met</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>529</Position>
      <Original>Val</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>651</Position>
      <Original>Leu</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>865</Position>
      <Original>Ser</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>536</Position>
      <Original>Gln</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>186</Position>
      <Original>Pro</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>444</Position>
      <Original>Ala</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>625</Position>
      <Original>Arg</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>347</Position>
      <Original>Cys</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>660</Position>
      <Original>Val</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>120</Position>
      <Original>Ala</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>344</Position>
      <Original>Ser</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>50</Position>
      <Original>Ala</Original>
      <Variation>Thr</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>The cellular synthesis of either RNA on a template of DNA or DNA on a template of RNA.</Detail>
      <Keyword>Transcription</Keyword>
      <Ontology_ID>GO:0006350</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of the synthesis of either RNA on a template of DNA or DNA on a template of RNA.</Detail>
      <Keyword>Regulation of transcription</Keyword>
      <Ontology_ID>GO:0045449</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that mediates the transfer of information from one cell to another.</Detail>
      <Keyword>Cell-cell signaling</Keyword>
      <Ontology_ID>GO:0007267</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process involved in the assembly of the RNA polymerase II preinitiation complex (PIC) at an RNA polymerase II promoter region of a DNA template, resulting in the subsequent synthesis of RNA from that promoter. The initiation phase includes PIC assembly and the formation of the first few bonds in the RNA chain, including abortive initiation, which occurs when the first few nucleotides are repeatedly synthesized and then released. Promoter clearance, or release, is the transition between the initiation and elongation phases of transcription.</Detail>
      <Keyword>Transcription initiation from RNA polymerase II promoter</Keyword>
      <Ontology_ID>GO:0006367</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product or products (proteins or RNA). This includes the production of an RNA transcript as well as any processing to produce a mature RNA product or an mRNA (for protein-coding genes) and the translation of that mRNA into protein. Some protein processing events may be included when they are required to form an active form of a product from an inactive precursor form.</Detail>
      <Keyword>Negative regulation of gene expression</Keyword>
      <Ontology_ID>GO:0010629</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>190</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>213</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>102</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>130</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>676</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>294</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>162</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>81</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>345</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>20</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>400</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MTELKAKGPRAPHVAGGPPSPEVGSPLLCRPAAGPFPGSQTSDTLPEVSAIPISLDGLLFPRPCQGQDPSDEKTQDQQSLSDVEGAYSRAEATRGAGGSSSSPPEKDSGLLDSVLDTLLAPSGPGQSQPSPPACEVTSSWCLFGPELPEDPPAAPATQRVLSPLMSRSGCKVGDSSGTAAAHKVLPRGLSPARQLLLPASESPHWSGAPVKPSPQAAAVEVEEEDGSESEESAGPLLKGKPRALGGAAAGGGAAAVPPGAAAGGVALVPKEDSRFSAPRVALVEQDAPMAPGRSPLATTVMDFIHVPILPLNHALLAARTRQLLEDESYDGGAGAASAFAPPRSSPCASSTPVAVGDFPDCAYPPDAEPKDDAYPLYSDFQPPALKIKEEEEGAEASARSPRSYLVAGANPAAFPDFPLGPPPPLPPRATPSRPGEAAVTAAPASASVSSASSSGSTLECILYKAEGAPPQQGPFAPPPCKAPGASGCLLPRDGLPSTSASAAAAGAAPALYPALGLNGLPQLGYQAAVLKEGLPQVYPPYLNYLRPDSEASQSPQYSFESLPQKICLICGDEASGCHYGVLTCGSCKVFFKRAMEGQHNYLCAGRNDCIVDKIRRKNCPACRLRKCCQAGMVLGGRKFKKFNKVRVVRALDAVALPQPVGVPNESQALSQRFTFSPGQDIQLIPPLINLLMSIEPDVIYAGHDNTKPDTSSSLLTSLNQLGERQLLSVVKWSKSLPGFRNLHIDDQITLIQYSWMSLMVFGLGWRSYKHVSGQMLYFAPDLILNEQRMKESSFYSLCLTMWQIPQEFVKLQVSQEEFLCMKVLLLLNTIPLEGLRSQTQFEEMRSSYIRELIKAIGLRQKGVVSSSQRFYQLTKLLDNLHDLVKQLHLYCLNTFIQSRALSVEFPEMMSEVIAAQLPKILAGMVKPLLFHKK</Protein_Seq>
    <DNA_Seq>AGTCCACAGCTGTCACTAATCGGGGTAAGCCTTGTTGTATTTGTGCGTGTGGGTGGCATTCTCAATGAGAACTAGCTTCACTTGTCATTTGAGTGAAATCTACAACCCGAGGCGGCTAGTGCTCCCGCACTACTGGGATCTGAGATCTTCGGAGATGACTGTCGCCCGCAGTACGGAGCCAGCAGAAGTCCGACCCTTCCTGGGAATGGGCTGTACCGAGAGGTCCGACTAGCCCCAGGGTTTTAGTGAGGGGGCAGTGGAACTCAGCGAGGGACTGAGAGCTTCACAGCATGCACGAGTTTGATGCCAGAGAAAAAGTCGGGAGATAAAGGAGCCGCGTGTCACTAAATTGCCGTCGCAGCCGCAGCCACTCAAGTGCCGGACTTGTGAGTACTCTGCGTCTCCAGTCCTCGGACAGAAGTTGGAGAACTCTCTTGGAGAACTCCCCGAGTTAGGAGACGAGATCTCCTAACAATTACTACTTTTTCTTGCGCTCCCCACTTGCCGCTCGCTGGGACAAACGACAGCCACAGTTCCCCTGACGACAGGATGGAGGCCAAGGGCAGGAGCTGACCAGCGCCGCCCTCCCCCGCCCCCGACCCAGGAGGTGGAGATCCCTCCGGTCCAGCCACATTCAACACCCACTTTCTCCTCCCTCTGCCCCTATATTCCCGAAACCCCCTCCTCCTTCCCTTTTCCCTCCTCCTGGAGACGGGGGAGGAGAAAAGGGGAGTCCAGTCGTCATGACTGAGCTGAAGGCAAAGGGTCCCCGGGCTCCCCACGTGGCGGGCGGCCCGCCCTCCCCCGAGGTCGGATCCCCACTGCTGTGTCGCCCAGCCGCAGGTCCGTTCCCGGGGAGCCAGACCTCGGACACCTTGCCTGAAGTTTCGGCCATACCTATCTCCCTGGACGGGCTACTCTTCCCTCGGCCCTGCCAGGGACAGGACCCCTCCGACGAAAAGACGCAGGACCAGCAGTCGCTGTCGGACGTGGAGGGCGCATATTCCAGAGCTGAAGCTACAAGGGGTGCTGGAGGCAGCAGTTCTAGTCCCCCAGAAAAGGACAGCGGACTGCTGGACAGTGTCTTGGACACTCTGTTGGCGCCCTCAGGTCCCGGGCAGAGCCAACCCAGCCCTCCCGCCTGCGAGGTCACCAGCTCTTGGTGCCTGTTTGGCCCCGAACTTCCCGAAGATCCACCGGCTGCCCCCGCCACCCAGCGGGTGTTGTCCCCGCTCATGAGCCGGTCCGGGTGCAAGGTTGGAGACAGCTCCGGGACGGCAGCTGCCCATAAAGTGCTGCCCCGGGGCCTGTCACCAGCCCGGCAGCTGCTGCTCCCGGCCTCTGAGAGCCCTCACTGGTCCGGGGCCCCAGTGAAGCCGTCTCCGCAGGCCGCTGCGGTGGAGGTTGAGGAGGAGGATGGCTCTGAGTCCGAGGAGTCTGCGGGTCCGCTTCTGAAGGGCAAACCTCGGGCTCTGGGTGGCGCGGCGGCTGGAGGAGGAGCCGCGGCTGTCCCGCCGGGGGCGGCAGCAGGAGGCGTCGCCCTGGTCCCCAAGGAAGATTCCCGCTTCTCAGCGCCCAGGGTCGCCCTGGTGGAGCAGGACGCGCCGATGGCGCCCGGGCGCTCCCCGCTGGCCACCACGGTGATGGATTTCATCCACGTGCCTATCCTGCCTCTCAATCACGCCTTATTGGCAGCCCGCACTCGGCAGCTGCTGGAAGACGAAAGTTACGACGGCGGGGCCGGGGCTGCCAGCGCCTTTGCCCCGCCGCGGAGTTCACCCTGTGCCTCGTCCACCCCGGTCGCTGTAGGCGACTTCCCCGACTGCGCGTACCCGCCCGACGCCGAGCCCAAGGACGACGCGTACCCTCTCTATAGCGACTTCCAGCCGCCCGCTCTAAAGATAAAGGAGGAGGAGGAAGGCGCGGAGGCCTCCGCGCGCTCCCCGCGTTCCTACCTTGTGGCCGGTGCCAACCCCGCAGCCTTCCCGGATTTCCCGTTGGGGCCACCGCCCCCGCTGCCGCCGCGAGCGACCCCATCCAGACCCGGGGAAGCGGCGGTGACGGCCGCACCCGCCAGTGCCTCAGTCTCGTCTGCGTCCTCCTCGGGGTCGACCCTGGAGTGCATCCTGTACAAAGCGGAGGGCGCGCCGCCCCAGCAGGGCCCGTTCGCGCCGCCGCCCTGCAAGGCGCCGGGCGCGAGCGGCTGCCTGCTCCCGCGGGACGGCCTGCCCTCCACCTCCGCCTCTGCCGCCGCCGCCGGGGCGGCCCCCGCGCTCTACCCTGCACTCGGCCTCAACGGGCTCCCGCAGCTCGGCTACCAGGCCGCCGTGCTCAAGGAGGGCCTGCCGCAGGTCTACCCGCCCTATCTCAACTACCTGAGGCCGGATTCAGAAGCCAGCCAGAGCCCACAATACAGCTTCGAGTCATTACCTCAGAAGATTTGTTTAATCTGTGGGGATGAAGCATCAGGCTGTCATTATGGTGTCCTTACCTGTGGGAGCTGTAAGGTCTTCTTTAAGAGGGCAATGGAAGGGCAGCACAACTACTTATGTGCTGGAAGAAATGACTGCATCGTTGATAAAATCCGCAGAAAAAACTGCCCAGCATGTCGCCTTAGAAAGTGCTGTCAGGCTGGCATGGTCCTTGGAGGTCGAAAATTTAAAAAGTTCAATAAAGTCAGAGTTGTGAGAGCACTGGATGCTGTTGCTCTCCCACAGCCAGTGGGCGTTCCAAATGAAAGCCAAGCCCTAAGCCAGAGATTCACTTTTTCACCAGGTCAAGACATACAGTTGATTCCACCACTGATCAACCTGTTAATGAGCATTGAACCAGATGTGATCTATGCAGGACATGACAACACAAAACCTGACACCTCCAGTTCTTTGCTGACAAGTCTTAATCAACTAGGCGAGAGGCAACTTCTTTCAGTAGTCAAGTGGTCTAAATCATTGCCAGGTTTTCGAAACTTACATATTGATGACCAGATAACTCTCATTCAGTATTCTTGGATGAGCTTAATGGTGTTTGGTCTAGGATGGAGATCCTACAAACACGTCAGTGGGCAGATGCTGTATTTTGCACCTGATCTAATACTAAATGAACAGCGGATGAAAGAATCATCATTCTATTCATTATGCCTTACCATGTGGCAGATCCCACAGGAGTTTGTCAAGCTTCAAGTTAGCCAAGAAGAGTTCCTCTGTATGAAAGTATTGTTACTTCTTAATACAATTCCTTTGGAAGGGCTACGAAGTCAAACCCAGTTTGAGGAGATGAGGTCAAGCTACATTAGAGAGCTCATCAAGGCAATTGGTTTGAGGCAAAAAGGAGTTGTGTCGAGCTCACAGCGTTTCTATCAACTTACAAAACTTCTTGATAACTTGCATGATCTTGTCAAACAACTTCATCTGTACTGCTTGAATACATTTATCCAGTCCCGGGCACTGAGTGTTGAATTTCCAGAAATGATGTCTGAAGTTATTGCTGCACAATTACCCAAGATATTGGCAGGGATGGTGAAACCCCTTCTCTTTCATAAAAAGTGAATGTCATCTTTTTCTTTTAAAGAATTAAATTTTGTGGTATGTCTTTTTGTTTTGGTCAGGATTATGAGGTCTTGAGTTTTTATAATGTTCTTCTGAAAGCCTTACATTTATAACATCATAGTGTGTAAATTTAAAAGAAAAATTGTGAGGTTCTAATTATTTTCTTTTATAAAGTATAATTAGAATGTTTAACTGTTTTGTTTACCCATATTTTCTTGAAGAATTTACAAGATTGAAAAAGTACTAAAATTGTTAAAGTAAACTATCTTATCCATATTATTTCATACCATGTAGGTGAGGATTTTTAACTTTTGCATCTAACAAATCATCGACTTAAGAGAAAAAATCTTACATGTAATAACACAAAGCTATTATATGTTATTTCTAGGTAACTCCCTTTGTGTCAATTATATTTCCAAAAATGAACCTTTAAAATGGTATGCAAAATTTTGTCTATATATATTTGTGTGAGGAGGAAATTCATAACTTTCCTCAGATTTTCAAAAGTATTTTTAATGCAAAAAATGTAGAAAGAGTTTAAAACCACTAAAATAGATTGATGTTCTTCAAACTAGGCAAAACAACTCATATGTTAAGACCATTTTCCAGATTGGAAACACAAATCTCTTAGGAAGTTAATAAGTAGATTCATATCATTATGCAAATAGTATTGTGGGTTTTGTAGGTTTTTAAAATAACCTTTTTTGGGGAGAGAATTGTCCTCTAATGAGGTATTGCGAGTGGACATAAGAAATCAGAAGATTATGGCCTAACTGTACTCCTTACCAACTGTGGCATGCTGAAAGTTAGTCACTCTTACTGATTCTCAATTCTCTCACCTTTGAAAGTAGTAAAATATCTTTCCTGCCAATTGCTCCTTTGGGTCAGAGCTTATTAACATCTTTTCAAATCAAAGGAAAGAAGAAAGGGAGAGGAGGAGGAGGGAGGTATCAATTCACATACCTTTCTCCTCTTTATCCTCCACTATCATGAATTCATATTATGTTTCAGCCATGCAAATCTTTTTACCATGAAATTTCTTCCAGAATTTTCCCCCTTTGACACAAATTCCATGCATGTTTCAACCTTCGAGACTCAGCCAAATGTCATTTCTGTAAAATCTTCCCTGAGTCTTCCAAGCAGTAATTTGCCTTCTCCTAGAGTTTACCTGCCATTTTGTGCACATTTGAGTTACAGTAGCATGTTATTTTACAATTGTGACTCTCCTGGGAGTCTGGGAGCCATATAAAGTGGTCAATAGTGTTTGCTGACTGAGAGTTGAATGACATTTTCTCTCTGTCTTGGTATTACTGTAGATTTCGATCATTCTTTGGTTACATTTCTGCATATTTCTGTACCCATGACTTTATCACTTTCTTCTCCCATGCTTTATCTCCATCAATTATCTTCATTACTTTTAAATTTTCCACCTTTGCTTCCTACTTTGTGAGATCTCTCCCTTTACTGACTATAACATAGAAGAATAGAAGTGTATTTTATGTGTCTTAAGGACAATACTTTAGATTCCTTGTTCTAAGTTTTTAAACTGAATGAATGGAATATTATTTCTCTCCCTAAGCAAAATTCCACAAAACAATTATTTCTTATGTTTATGTAGCCTTAAATTGTTTTGTACTGTAAACCTCAGCATAAAAACTTTCTTCATTTCTAATTTCATTCAACAAATATTGATTGAATACCTGGTATTAGCACAAGAAAAATGTGCTAATAAGCCTTATGAGAATTTGGAGCTGAAGAAAGACATATAACTCAGGAAAGTTACAGTCCAGTAGTAGGTATAAATTACAGTGCCTGATAAATAGGCATTTTAATATTTGTACACTCAACGTATACTAGGTAGGTGCAAAACATTTACATATAATTTTACTGATACCCATGCAGCACAAAGGTACTAACTTTAAATATTAAATAACACCTTTATGTGTCAGTAATTCATTTGCATTAAATCTTATTGAAAAGGCTTTCAATATATTTTCCCCACAAATGTCATCCCAAGAAAAAAGTATTTTTAACATCTCCCAAATATAATAGTTACAGGAAATCTACCTCTGTGAGAGTGACACCTCTCAGAATGAACTGTGTGACACAAGAAAATGAATGTAGGTCTATCCAAAAAAAACCCCAAGAAACAAAAACAATATTATTAGCCCTTTATGCTTAAGTGATGGACTCAGGGAACAGTTGATGTTGTGATCATTTTATTATCTGATTCTTGTTACTTTGAATTAAACCAATATTTTGATGATATAAATCATTTCCACCAGCATATATTTAATTTCCATAATAACTTTAAAATTTTCTAATTTCACTCAACTATGAGGGAATAGAATGTGGTGGCCACAGGTTTGGCTTTTGTTAAAATGTTTGATATCTTCGATGTTGATCTCTGTCTGCAATGTAGATGTCTAAACACTAGGATTTAATATTTAAGGCTAAGCTTTAAAAATAAAGTACCTTTTTAAAAAGAATATGGCTTCACCAAATGGAAAATACCTAATTTCTAAATCTTTTTCTCTACAAAGTCCTATCTACTAATGTCTCCATTACTATTTAGTCATCATAACCATTATCTTCATTTTACATGTCGTGTTCTTTCTGGTAGCTCTAAAATGACACTAAATCATAAGAAGACAGGTTACATATCAGGAAATACTTGAAGGTTACTGAAATAGATTCTTGAGTTAATGAAAATATTTTCTGTAAAAAGGTTTGAAAAGCCATTTGAGTCTAAAGCATTATACCTCCATTATCAGTAGTTATGTGACAATTGTGTGTGTGTTTAATGTTTAAAGATGTGGCACTTTTTAATAAGGCAATGCTATGCTATTTTTTCCCATTTAACATTAAGATAATTTATTGCTATACAGATGATATGGAAATATGATGAACAATATTTTTTTTGCCAAAACTATGCCTTGTAAGTAGCCATGGAATGTCAACCTGTAACTTAAATTATCCACAGATAGTCATGTGTTTGATGATGGGCACTGTGGAGATAACTGACATAGGACTGTGCCCCCCTTCTCTGCCACTTACTAGCTGGATGAGATTAAGCAAGTCATTTAACTGCTCTGATTAAACCTGCCTTTCCCAAGTGCTTTGTAATGAATAGAAATGGAAACCAAAAAAAACGTATACAGGCCTTCAGAAATAGTAATTGCTACTATTTTGTTTTCATTAAGCCATAGTTCTGGCTATAATTTTATCAAACTCACCAGCTATATTCTACAGTGAAAGCAGGATTCTAGAAAGTCTCACTGTTTTATTTATGTCACCATGTGCTATGATATATTTGGTTGAATTCATTTGAAATTAGGGCTGGAAGTATTCAAGTAATTTCTTCTGCTGAAAAAATACAGTGTTTTGAGTTTAGGGCCTGTTTTATCAAAGTTCTAAAGAGCCTATCACTCTTCCATTGTAGACATTTTAAAATAATGACACTGATTTTAACATTTTTAAGTGTCTTTTTAGAACAGAGAGCCTGACTAGAACACAGCCCCTCCAAAAACCCATGCTCAAATTATTTTTACTATGGCAGCAATTCCACAAAAGGGAACAATGGGTTTAGAAATTACAATGAAGTCATCAACCCAAAAAACATCCCTATCCCTAAGAAGGTTATGATATAAAATGCCCACAAGAAATCTATGTCTGCTTTAATCTGTCTTTTATTGCTTTGGAAGGATGGCTATTACATTTTTAGTTTTTGCTGTGAATACCTGAGCAGTTTCTCTCATCCATACTTATCCTTCACACATCAGAAGTCAGGATAGAATATGAATCATTTTAAAAACTTTTACAACTCCAGAGCCATGTGCATAAGAAGCATTCAAAACTTGCCAAAACATACATTTTTTTTCAAATTTAAAGATACTCTATTTTTGTATTCAATAGCTCAACAACTGTGGTCCCCACTGATAAAGTGAAGTGGACAAGGAGACAAGTAATGGCATAAGTTTGTTTTTCCCAAAGTATGCCTGTTCAATAGCCATTGGATGTGGGAAATTTCTACATCTCTTAAAATTTTACAGAAAATACATAGCCAGATAGTCTAGCAAAAGTTCACCAAGTCCTAAATTGCTTATCCTTACTTCACTAAGTCATGAAATCATTTTAATGAAAAGAACATCACCTAGGTTTTGTGGTTTCTTTTTTTCTTATTCATGGCTGAGTGAAAACAACAATCTCTGTTTCTCCCTAGCATCTGTGGACTATTTAATGTACCATTATTCCACACTCTATGGTCCTTACTAAATACAAAATTGAACAAAAAGCAGTAAAACAACTGACTCTTCACCCATATTATAAAATATAATCCAAGCCAGATTAGTCAACATCCATAAGATGAATCCAAGCTGAACTGGGCCTAGATTATTGAGTTCAGGTTGGATCACATCCCTATTTATTAATAAACTTAGGAAAGAAGGCCTTACAGACCATCAGTTAGCTGGAGCTAATAGAACCTACACTTCTAAAGTTCGGCCTAGAATCAATGTGGCCTTAAAAGCTGAAAAGAAGCAGGAAAGAACAGTTTTCTTCAATAATTTGTCCACCCTGTCACTGGAGAAAATTTAAGAATTTGGGGGTGTTGGTAGTAAGTTAAACACAGCAGCTGTTCATGGCAGAAATTATTCAATACATACCTTCTCTGAATATCCTATAACCAAAGCAAAGAAAAACACCAAGGGGTTTGTTCTCCTCCTTGGAGTTGACCTCATTCCAAGGCAGAGCTCAGGTCACAGGCACAGGGGCTGCGCCCAAGCTTGTCCGCAGCCTTATGCAGCTGTGGAGTCTGGAAGACTGTTGCAGGACTGCTGGCCTAGTCCCAGAATGTCAGCCTCATTTTCGATTTACTGGCTCTTGTTGCTGTATGTCATGCTGACCTTATTGTTAAACACAGGTTTGTTTGCTTTTTTTCCACTCATGGAGACATGGGAGAGGCATTATTTTTAAGCTGGTTGAAAGCTTTAACCGATAAAGCATTTTTAGAGAAATGTGAATCAGGCAGCTAAGAAAGCATACTCTGTCCATTACGGTAAAGAAAATGCACAGATTATTAACTCTGCAGTGTGGCATTAGTGTCCTGGTCAATATTCGGATAGATATGAATAAAATATTTAAATGGTATTGTAAATAGTTTTCAGGACATATGCTATAGCTTATTTTTATTATCTTTTGAAATTGCTCTTAATACATCAAATCCTGATGTATTCAATTTATCAGATATAAATTATTCTAAATGAAGCCCAGTTAAATGTTTTTGTCTTGTCAGTTATATGTTAAGTTTCTGATCTCTTTGTCTATGACGTTTACTAATCTGCATTTTTACTGTTATGAATTATTTTAGACAGCAGTGGTTTCAAGCTTTTTGCCACTAAAAATACCTTTTATTTTCTCCTCCCCCAGAAAAGTCTATACCTTGAAGTATCTATCCACCAAACTGTACTTCTATTAAGAAATAGTTATTGTGTTTTCTTAATGTTTTGTTATTCAAAGACATATCAATGAAAGCTGCTGAGCAGCATGAATAACAATTATATCCACACAGATTTGATATATTTTGTGCAGCCTTAACTTGATAGTATAAAATGTCATTGCTTTTTAAATAATAGTTAGTCAATGGACTTCTATCATAGCTTTCCTAAACTAGGTTAAGATCCAGAGCTTTGGGGTCATAATATATTACATACAATTAAGTTATCTTTTTCTAAGGGCTTTAAAATTCATGAGAATAACCAAAAAAGGTATGTGGAGAGTTAATACAAACATACCATATTCTTGTTGAAACAGAGATGTGGCTCTGCTTGTTCTCCATAAGGTAGAAATACTTTCCAGAATTTGCCTAAACTAGTAAGCCCTGAATTTGCTATGATTAGGGATAGGAAGAGATTTTCACATGGCAGACTTTAGAATTCTTCACTTTAGCCAGTAAAGTATCTCCTTTTGATCTTAGTATTCTGTGTATTTTAACTTTTCTGAGTTGTGCATGTTTATAAGAAAAATCAGCACAAAGGGTTTAAGTTAAAGCCTTTTTACTGAAATTTGAAAGAAACAGAAGAAAATATCAAAGTTCTTTGTATTTTGAGAGGATTAAATATGATTTACAAAAGTTACATGGAGGGCTCTCTAAAACATTAAATTAATTATTTTTTGTTGAAAAGTCTTACTTTAGGCATCATTTTATTCCTCAGCAACTAGCTGTGAAGCCTTTACTGTGCTGTATGCCAGTCACTCTGCTAGATTGTGGAGATTACCAGTGTTCCCGTCTTCTCCGAGCTTAGAGTTGGATGGGGAATAAAGACAGGTAAACAGATAGCTACAATATTGTACTGTGAATGCTTATGCTGGAGGAAGTACAGGGAACTATTGGAGCACCTAAGAGGAGCACCTACCTTGAATTTAGGGGTTAGCAGAGGCATCCTGAAAAAAGTCAAAGCTAAGCCACAATCTATAAGCAGTTTAGGAATTAGCAGAACGTGCGTGGTGAGGAGATGCCAAAGGCAAGAAGAGAAGAGTATTCCAAACAGGAGGGATTCCAAAGAGAGAAGAGTATCCCAAACAACATTTGCACAAACCTGATGGGGAGAGAGAATGTGGGGTGGGGATGGATGATGAGACTGAAGAAGAAAGCCAGGTCTAGATAATCAGTGGCCTTGTACACCATGTTAAAGAGTGTAGACTTGATTCTGTTGTAAACAGGAAAGCAGCACAATTCATATGAATATTTTAGAAGACTCCCACTGGAATATGGAGAATAAAGTTGGAGATGACTAATCCTGGAAGCAGGGAGAACATTTTTGAGGAAGTTGCACTATTTTGGTGAAAATGATGATCATAAACATGAAGAATTGTAGGTGATCATGACCTCCTCTCTAATTTTCCAGAAGGGTTTTGGAAGATATAACATAGGAACATTGACAGGACTGACGAAAGGAGATGAAATACACCATATAAATTGTCAAACACAAGGCCAGATGTCTAATTATTTTGCTTATGTGTTGAAATTACAAATTTTTCATCAGGAAACCAAAAACTACAAAACTTAGTTTTCCCAAGTCCCAGAATTCTATCTGTCCAAACAATCTGTACCACTCCACCTATATCCCTACCTTTGCATGTCTGTCCAACCTCAAAGTCCAGGTCTATACACACGGGTAAGACTAGAGCAGTTCAAGTTTCAGAAAATGAGAAAGAGGAACTGAGTTGTGCTGAACCCATACAAAATAAACACATTCTTTGTATAGATTCTTGGAACCTCGAGAGGAATTCACCTAACTCATAGGTATTTGATGGTATGAATCCATGGCTGGGCTCGGCTTTTAAAAAGCCTTATCTGGGATTCCTTCTATGGAACCAAGTTCCATCAAAGCCCATTTAAAAGCCTACATTAAAAACAAAATTCTTGCTGCATTGTATACAAATAATGATGTCATGATCAAATAATCAGATGCCATTATCAAGTGGAATTACAAAATGGTATACCCACTCCAAAAAAAAAAAAAAAGCTAAATTCTCAGTAGAACATTGTGACTTCATGAGCCCTCCACAGCCTTGGAGCTGAGGAGGGAGCACTGGTGAGCAGTAGGTTGAAGAGAAAACTTGGCGCTTAATAATCTATCCATGTTTTTTCATCTAAAAGAGCCTTCTTTTTGGATTACCTTATTCAATTTCCATCAAGGAAATTGTTAGTTCCACTAACCAGACAGCAGCTGGGAAGGCAGAAGCTTACTGTATGTACATGGTAGCTGTGGGAAGGAGGTTTCTTTCTCCAGGTCCTCACTGGCCATACACCAGTCCCTTGTTAGTTATGCCTGGTCATAGACCCCCGTTGCTATCATCTCATATTTAAGTCTTTGGCTTGTGAATTTATCTATTCTTTCAGCTTCAGCACTGCAGAGTGCTGGGACTTTGCTAACTTCCATTTCTTGCTGGCTTAGCACATTCCTCATAGGCCCAGCTCTTTTCTCATCTGGCCCTGCTGTGGAGTCACCTTGCCCCTTCAGGAGAGCCATGGCTTACCACTGCCTGCTAAGCCTCCACTCAGCTGCCACCACACTAAATCCAAGCTTCTCTAAGATGTTGCAGACTTTACAGGCAAGCATAAAAGGCTTGATCTTCCTGGACTTCCCTTTACTTGTCTGAATCTCACCTCCTTCAACTTTCAGTCTCAGAATGTAGGCATTTGTCCTCTTTGCCCTACATCTTCCTTCTTCTGAATCATGAAAGCCTCTCACTTCCTCTTGCTATGTGCTGGAGGCTTCTGTCAGGTTTTAGAATGAGTTCTCATCTAGTCCTAGTAGCTTTTGATGCTTAAGTCCACCTTTTAAGGATACCTTTGAGATTTAGACCATGTTTTTCGCTTGAGAAAGCCCTAATCTCCAGACTTGCCTTTCTGTGGATTTCAAAGACCAACTGAGGAAGTCAAAAGCTGAATGTTGACTTTCTTTGAACATTTCCGCTATAACAATTCCAATTCTCCTCAGAGCAATATGCCTGCCTCCAACTGACCAGGAGAAAGGTCCAGTGCCAAAGAGAAAAACACAAAGATTAATTATTTCAGTTGAGCACATACTTTCAAAGTGGTTTGGGTATTCATATGAGGTTTTCTGTCAAGAGGGTGAGACTCTTCATCTATCCATGTGTGCCTGACAGTTCTCCTGGCACTGGCTGGTAACAGATGCAAAACTGTAAAAATTAAGTGATCATGTATTTTAACGATATCATCACATACTTATTTTCTATGTAATGTTTTAAATTTCCCCTAACATACTTTGACTGTTTTGCACATGGTAGATATTCACATTTTTTTGTGTTGAAGTTGATGCAATCTTCAAAGTTATCTACCCCGTTGCTTATTAGTAAAACTAGTGTTAATACTTGGCAAGAGATGCAGGGAATCTTTCTCATGACTCACGCCCTATTTAGTTATTAATGCTACTACCCTATTTTGAGTAAGTAGTAGGTCCCTAAGTACATTGTCCAGAGTTATACTTTTAAAGATATTTAGCCCCATATACTTCTTGAATCTAAAGTCATACACCTTGCTCCTCATTTCTGAGTGGGAAAGACATTTGAGAGTATGTTGACAATTGTTCTGAAGGTTTTTGCCAAGAAGGTGAAACTGTCCTTTCATCTGTGTATGCCTGGGGCTGGGTCCCTGGCAGTGATGGGGTGACAATGCAAAGCTGTAAAAACTAGGTGCTAGTGGGCACCTAATATCATCATCATATACTTATTTTCAAGCTAATATGCAAAATCCCATCTCTGTTTTTAAACTAAGTGTAGATTTCAGAGAAAATATTTTGTGGTTCACATAAGAAAACAGTCTACTCAGCTTGACAAGTGTTTTATGTTAAATTGGCTGGTGGTTTGAAATGAATCATCTTCACATAATGTTTTCTTTAAAAATATTGTGAATTTAACTCTAATTCTTGTTATTCTGTGTGATAATAAAGAATAAACTAATTTCTA</DNA_Seq>
  </Molecule_Seq>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleus</CellLocal>
      <Ontology_ID>GO:0005634</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytoplasm</CellLocal>
      <Ontology_ID>GO:0005737</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleoplasm</CellLocal>
      <Ontology_ID>GO:0005654</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>PGR</Gene_Name>
    <Gene_Alias>NR3C3</Gene_Alias>
    <Gene_ID>5241</Gene_ID>
    <Genbank_ACCN>NM_000926</Genbank_ACCN>
    <Protein_ACCN>NP_000917</Protein_ACCN>
    <HGNC_ID>8910</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/5241</Gene_URL>
    <UCSC_ID>uc001pgh.2</UCSC_ID>
    <EMBL_ID>ENSG00000082175</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>Q9H467</Uniprot_ID>
      <Gene_Name>CUEDC2</Gene_Name>
      <EBI_ID>EBI-1248228</EBI_ID>
      <PPI_EBI_URL>EBI-78539,EBI-1248228</PPI_EBI_URL>
      <Experiment_Number>9</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Cribriform Carcinoma</Disease_Name>
      <Disease_Detail>Cribriform Carcinoma</Disease_Detail>
      <Disease_DB>CRB006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cribriform_carcinoma?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Ovarian Carcinosarcoma</Disease_Name>
      <Disease_Detail>Ovarian Cancer</Disease_Detail>
      <Disease_DB>OVR044</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/ovarian_carcinosarcoma?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Adenofibroma</Disease_Name>
      <Disease_Detail>Adenofibroma</Disease_Detail>
      <Disease_DB>ADN017</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/adenofibroma?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Leiomyoma</Disease_Name>
      <Disease_Detail>Leiomyoma</Disease_Detail>
      <Disease_DB>LMY002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/leiomyoma?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Ovarian Serous Cystadenocarcinoma</Disease_Name>
      <Disease_Detail>Ovarian Cancer</Disease_Detail>
      <Disease_DB>OVR012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/ovarian_serous_cystadenocarcinoma?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Secretory Meningioma</Disease_Name>
      <Disease_Detail>Secretory Meningioma</Disease_Detail>
      <Disease_DB>SCR001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/secretory_meningioma?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Endometrial Carcinoma</Disease_Name>
      <Disease_Detail>Endometrial Cancer</Disease_Detail>
      <Disease_DB>END042</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/endometrial_carcinoma?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Breast Disease</Disease_Name>
      <Disease_Detail>Breast Disease</Disease_Detail>
      <Disease_DB>BRS051</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/breast_disease?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Trigonitis</Disease_Name>
      <Disease_Detail>Trigonitis</Disease_Detail>
      <Disease_DB>TRG001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/trigonitis?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Primary Pigmented Nodular Adrenocortical Disease</Disease_Name>
      <Disease_Detail>Primary Pigmented Nodular Adrenocortical Disease</Disease_Detail>
      <Disease_DB>PRM051</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/primary_pigmented_nodular_adrenocortical_disease?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Cystadenocarcinoma</Disease_Name>
      <Disease_Detail>Cystadenoma</Disease_Detail>
      <Disease_DB>CYS014</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cystadenocarcinoma?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Glassy Cell Carcinoma of the Cervix</Disease_Name>
      <Disease_Detail>Glassy Cell Carcinoma of the Cervix</Disease_Detail>
      <Disease_DB>GLS012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/glassy_cell_carcinoma_of_the_cervix?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Papillary Serous Adenocarcinoma</Disease_Name>
      <Disease_Detail>Papillary Serous Adenocarcinoma</Disease_Detail>
      <Disease_DB>PPL007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/papillary_serous_adenocarcinoma?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Endometriosis</Disease_Name>
      <Disease_Detail>Endometriosis</Disease_Detail>
      <Disease_DB>END044</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/endometriosis?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Adenosarcoma</Disease_Name>
      <Disease_Detail>Adenosarcoma</Disease_Detail>
      <Disease_DB>ADN020</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/adenosarcoma?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Sertoli-Leydig Cell Tumor</Disease_Name>
      <Disease_Detail>Sertoli-Leydig Cell Tumor</Disease_Detail>
      <Disease_DB>SRT003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/sertoli_leydig_cell_tumor?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Lymphangioleiomyomatosis</Disease_Name>
      <Disease_Detail>Lymphangioleiomyomatosis</Disease_Detail>
      <Disease_DB>LYM007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/lymphangioleiomyomatosis?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Mammary Paget's Disease</Disease_Name>
      <Disease_Detail>Mammary Paget's Disease</Disease_Detail>
      <Disease_DB>MMM001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/mammary_pagets_disease?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Breast Fibroadenoma</Disease_Name>
      <Disease_Detail>Breast Cancer</Disease_Detail>
      <Disease_DB>BRS053</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/breast_fibroadenoma?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Serous Cystadenocarcinoma</Disease_Name>
      <Disease_Detail>Serous Cystadenocarcinoma</Disease_Detail>
      <Disease_DB>SRS001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/serous_cystadenocarcinoma?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Mucinous Cystadenocarcinoma</Disease_Name>
      <Disease_Detail>Mucinous Cystadenocarcinoma</Disease_Detail>
      <Disease_DB>MCN008</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/mucinous_cystadenocarcinoma?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pancreatic Mucinous Cystadenoma</Disease_Name>
      <Disease_Detail>Pancreatic Cancer</Disease_Detail>
      <Disease_DB>PNC002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pancreatic_mucinous_cystadenoma?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Optic Nerve Sheath Meningioma</Disease_Name>
      <Disease_Detail>Optic Nerve Sheath Meningioma</Disease_Detail>
      <Disease_DB>OPT002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/optic_nerve_sheath_meningioma?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Gastric Leiomyosarcoma</Disease_Name>
      <Disease_Detail>Gastric Leiomyosarcoma</Disease_Detail>
      <Disease_DB>GST036</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/gastric_leiomyosarcoma?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Epithelioid Hemangioendothelioma</Disease_Name>
      <Disease_Detail>Epithelioid Hemangioendothelioma</Disease_Detail>
      <Disease_DB>EPT020</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/epithelioid_hemangioendothelioma?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Synchronous Bilateral Breast Carcinoma</Disease_Name>
      <Disease_Detail>Synchronous Bilateral Breast Carcinoma</Disease_Detail>
      <Disease_DB>SYN003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/synchronous_bilateral_breast_carcinoma?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Vulvar Dystrophy</Disease_Name>
      <Disease_Detail>Vulvar Dystrophy</Disease_Detail>
      <Disease_DB>VLV015</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/vulvar_dystrophy?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Cerebral Meningioma</Disease_Name>
      <Disease_Detail>Cerebral Meningioma</Disease_Detail>
      <Disease_DB>CRB036</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cerebral_meningioma?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Myoma</Disease_Name>
      <Disease_Detail>Myoma</Disease_Detail>
      <Disease_DB>MYM001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/myoma?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Cellular Leiomyoma</Disease_Name>
      <Disease_Detail>Cellular Leiomyoma</Disease_Detail>
      <Disease_DB>CLL005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cellular_leiomyoma?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Benign Metastasizing Leiomyoma</Disease_Name>
      <Disease_Detail>Benign Metastasizing Leiomyoma</Disease_Detail>
      <Disease_DB>BNG041</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/benign_metastasizing_leiomyoma?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Angiomyolipoma</Disease_Name>
      <Disease_Detail>Angiomyolipoma</Disease_Detail>
      <Disease_DB>ANG018</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/angiomyolipoma?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Juvenile Nasopharyngeal Angiofibroma</Disease_Name>
      <Disease_Detail>Juvenile Nasopharyngeal Angiofibroma</Disease_Detail>
      <Disease_DB>JVN033</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/juvenile_nasopharyngeal_angiofibroma?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Adenocarcinoma</Disease_Name>
      <Disease_Detail>Adenocarcinoma</Disease_Detail>
      <Disease_DB>ADN016</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/adenocarcinoma?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Primary Peritoneal Carcinoma</Disease_Name>
      <Disease_Detail>Primary Peritoneal Carcinoma</Disease_Detail>
      <Disease_DB>PRM126</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/primary_peritoneal_carcinoma?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Leiomyosarcoma</Disease_Name>
      <Disease_Detail>Leiomyosarcoma</Disease_Detail>
      <Disease_DB>LMY004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/leiomyosarcoma?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Acquired Hemophilia</Disease_Name>
      <Disease_Detail>Acquired Hemophilia</Disease_Detail>
      <Disease_DB>ACQ014</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acquired_hemophilia?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>in Situ Carcinoma</Disease_Name>
      <Disease_Detail>in Situ Carcinoma</Disease_Detail>
      <Disease_DB>INS002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/in_situ_carcinoma?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Spinal Meningioma</Disease_Name>
      <Disease_Detail>Spinal Meningioma</Disease_Detail>
      <Disease_DB>SPN021</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/spinal_meningioma?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Female Breast Carcinoma</Disease_Name>
      <Disease_Detail>Breast Cancer</Disease_Detail>
      <Disease_DB>FML027</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/female_breast_carcinoma?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Catamenial Pneumothorax</Disease_Name>
      <Disease_Detail>Catamenial Pneumothorax</Disease_Detail>
      <Disease_DB>CTM001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/catamenial_pneumothorax?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Endometrial Stromal Nodule</Disease_Name>
      <Disease_Detail>Endometrial Cancer</Disease_Detail>
      <Disease_DB>END003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/endometrial_stromal_nodule?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Ductal Carcinoma in Situ</Disease_Name>
      <Disease_Detail>Ductal Carcinoma in Situ</Disease_Detail>
      <Disease_DB>DCT002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/ductal_carcinoma_in_situ?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Arachnoid Cysts</Disease_Name>
      <Disease_Detail>Arachnoid Cysts</Disease_Detail>
      <Disease_DB>ARC007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/arachnoid_cysts?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Progesterone-Receptor Positive Breast Cancer</Disease_Name>
      <Disease_Detail>Progesterone-Receptor Positive Breast Cancer</Disease_Detail>
      <Disease_DB>PRG002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/progesterone_receptor_positive_breast_cancer?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Male Breast Cancer</Disease_Name>
      <Disease_Detail>Breast Cancer</Disease_Detail>
      <Disease_DB>MLB002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/male_breast_cancer?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Endometrial Stromal Sarcoma</Disease_Name>
      <Disease_Detail>Endometrial Cancer</Disease_Detail>
      <Disease_DB>END031</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/endometrial_stromal_sarcoma?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Kidney Angiomyolipoma</Disease_Name>
      <Disease_Detail>Kidney Cancer</Disease_Detail>
      <Disease_DB>KDN015</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/kidney_angiomyolipoma?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Progesterone Resistance</Disease_Name>
      <Disease_Detail>Progesterone Resistance</Disease_Detail>
      <Disease_DB>PRG014</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/progesterone_resistance?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Breast Cancer</Disease_Name>
      <Disease_Detail>Breast Cancer</Disease_Detail>
      <Disease_DB>BRS047</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/breast_cancer?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Meningioma</Disease_Name>
      <Disease_Detail>Meningioma</Disease_Detail>
      <Disease_DB>MNN012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/meningioma?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pleomorphic Lipoma</Disease_Name>
      <Disease_Detail>Pleomorphic Lipoma</Disease_Detail>
      <Disease_DB>PLM005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pleomorphic_lipoma?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Testicular Sex Cord-Stromal Tumor</Disease_Name>
      <Disease_Detail>Testicular Sex Cord-Stromal Tumor</Disease_Detail>
      <Disease_DB>TST037</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/testicular_sex_cord_stromal_tumor?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Bilateral Breast Cancer</Disease_Name>
      <Disease_Detail>Bilateral Breast Cancer</Disease_Detail>
      <Disease_DB>BLT006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/bilateral_breast_cancer?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Cystic Nephroma</Disease_Name>
      <Disease_Detail>Cystic Nephroma</Disease_Detail>
      <Disease_DB>CYS007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cystic_nephroma?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Sweat Gland Carcinoma</Disease_Name>
      <Disease_Detail>Sweat Gland Carcinoma</Disease_Detail>
      <Disease_DB>SWT001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/sweat_gland_carcinoma?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Microglandular Adenosis</Disease_Name>
      <Disease_Detail>Microglandular Adenosis</Disease_Detail>
      <Disease_DB>MCR019</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/microglandular_adenosis?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Gender Identity Disorder</Disease_Name>
      <Disease_Detail>Gender Identity Disorder</Disease_Detail>
      <Disease_DB>GND002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/gender_identity_disorder?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Adenocarcinoma in Situ</Disease_Name>
      <Disease_Detail>Adenocarcinoma</Disease_Detail>
      <Disease_DB>ADN012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/adenocarcinoma_in_situ?search=PGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Cystadenoma</Disease_Name>
      <Disease_Detail>Cystadenoma</Disease_Detail>
      <Disease_DB>CYS009</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cystadenoma?search=PGR#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Progesterone receptor ligand binding domain in complex with the nonsteroidal agonist tanaproget</PDB_Title>
      <PDB_ID>1ZUC</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ZUC</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Molecular and pharmacological properties of a potent and selective novel nonsteroidal progesterone receptor agonist tanaproget</PubMed_Title>
      <Author>Zhang, Z., et al.</Author>
      <Journal>J.Biol.Chem.(2005)280:28468-28475</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15937332?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF THE PROGESTERONE RECEPTOR-DNA COMPLEX</PDB_Title>
      <PDB_ID>2C7A</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2C7A</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of the Progesterone Receptor-Deoxyribonucleic Acid Complex: Novel Interactions Required for Binding to Half-Site Response Elements.</PubMed_Title>
      <Author>Roemer, S.C., et al.</Author>
      <Journal>Mol.Endocrinol.(2006)20:3042</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16931575?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>RU486 BOUND TO THE PROGESTERONE RECEPTOR IN A DESTABILIZED AGONISTIC CONFORMATION</PDB_Title>
      <PDB_ID>2W8Y</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2W8Y</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The X-Ray Structure of Ru486 Bound to the Progesterone Receptor in a Destabilized Agonistic Conformation.</PubMed_Title>
      <Author>Raaijmakers, H.C.A., et al.</Author>
      <Journal>J.Biol.Chem.(2009)284:19572</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19372222?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN PROGESTERON RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH THE LIGAND METRIBOLONE (R1881)</PDB_Title>
      <PDB_ID>1E3K</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1E3K</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Evidence for Ligand Specificity in the Binding Domain of the Human Androgen Receptor. Implications for Pathogenic Gene Mutations</PubMed_Title>
      <Author>Matias, P.M., et al.</Author>
      <Journal>J.Biol.Chem.(2000)275:26164</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10840043?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Progesterone Receptor Ligand Binding Domain with bound Norethindrone</PDB_Title>
      <PDB_ID>1SQN</PDB_ID>
      <Resolution>1.45</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1SQN</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Progesterone receptor ligand binding pocket flexibility: crystal structures of the norethindrone and mometasone furoate complexes</PubMed_Title>
      <Author>Madauss, K.P., et al.</Author>
      <Journal>J.Med.Chem.(2004)47:3381-3387</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15189034?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the human progesterone receptor ligand-binding domain bound to levonorgestrel</PDB_Title>
      <PDB_ID>3D90</PDB_ID>
      <Resolution>2.26</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3D90</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Met909 plays a key role in the activation of the progesterone receptor and also in the high potency of 13-ethyl progestins</PubMed_Title>
      <Author>Petit-Topin, I., et al.</Author>
      <Journal>Mol.Pharmacol.(2009)75:1317-1324</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19289570?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HORMONE-BOUND HUMAN PROGESTERONE RECEPTOR LIGAND-BINDING DOMAIN</PDB_Title>
      <PDB_ID>1A28</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1A28</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Atomic structure of progesterone complexed with its receptor.</PubMed_Title>
      <Author>Williams, S.P., et al.</Author>
      <Journal>Nature(1998)393:392-396</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9620806?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Progesterone Receptor with Bound Asoprisnil and a Peptide from the Co-Repressor SMRT</PDB_Title>
      <PDB_ID>2OVH</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2OVH</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator.</PubMed_Title>
      <Author>Madauss, K.P., et al.</Author>
      <Journal>Mol.Endocrinol.(2007)21:1066-1081</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17356170?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURAL BASIS FOR AGONISM AND ANTAGONISM FOR A SET OF CHEMICALLY RELATED PROGESTERONE RECEPTOR MODULATORS</PDB_Title>
      <PDB_ID>3ZRA</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3ZRA</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Basis for Agonism and Antagonism for a Set of Chemically Related Progesterone Receptor Modulators.</PubMed_Title>
      <Author>Lusher, S.J., et al.</Author>
      <Journal>J.Biol.Chem.(2011)286:35079</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21849509?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Progesterone Receptor with bound Pyrrolidine 1</PDB_Title>
      <PDB_ID>3G8O</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3G8O</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Rational design of orally-active, pyrrolidine-based progesterone receptor partial agonists.</PubMed_Title>
      <Author>Thompson, S.K., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2009)19:4777-4780</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19595590?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Progesterone Receptor with Bound Asoprisnil and a Peptide from the Co-Repressor NCoR</PDB_Title>
      <PDB_ID>2OVM</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2OVM</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator.</PubMed_Title>
      <Author>Madauss, K.P., et al.</Author>
      <Journal>Mol.Endocrinol.(2007)21:1066-1081</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17356170?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURAL BASIS FOR AGONISM AND ANTAGONISM FOR A SET OF CHEMICALLY RELATED PROGESTERONE RECEPTOR MODULATORS</PDB_Title>
      <PDB_ID>3ZRB</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3ZRB</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Basis for Agonism and Antagonism for a Set of Chemically Related Progesterone Receptor Modulators.</PubMed_Title>
      <Author>Lam, T.W., et al.</Author>
      <Journal>J.Biol.Chem.(2011)286:35079</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21849509?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Progesterone Receptor Hormone Binding Domain with Bound Mometasone Furoate</PDB_Title>
      <PDB_ID>1SR7</PDB_ID>
      <Resolution>1.46</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1SR7</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Progesterone receptor ligand binding pocket flexibility: crystal structures of the norethindrone and mometasone furoate complexes</PubMed_Title>
      <Author>Madauss, K.P., et al.</Author>
      <Journal>J.Med.Chem.(2004)47:3381-3387</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15189034?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURAL BASIS FOR AGONISM AND ANTAGONISM FOR A SET OF CHEMICALLY RELATED PROGESTERONE RECEPTOR MODULATORS</PDB_Title>
      <PDB_ID>3ZR7</PDB_ID>
      <Resolution>1.65</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3ZR7</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Basis for Agonism and Antagonism for a Set of Chemically Related Progesterone Receptor Modulators.</PubMed_Title>
      <Author>Lusher, S.J., et al.</Author>
      <Journal>J.Biol.Chem.(2011)286:35079</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21849509?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Progesterone Receptor bound to an Alkylpyrrolidine ligand.</PDB_Title>
      <PDB_ID>3HQ5</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3HQ5</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Rational design of orally-active, pyrrolidine-based progesterone receptor partial agonists.</PubMed_Title>
      <Author>Thompson, S.K., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2009)19:4777-4780</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19595590?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Progesterone receptor bound to sulfonamide pyrrolidine partial agonist</PDB_Title>
      <PDB_ID>3KBA</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3KBA</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Improving the developability profile of pyrrolidine progesterone receptor partial agonists.</PubMed_Title>
      <Author>Kallander, L.S., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2010)20:371-374</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19926282?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Progesterone Receptor with bound Pyrrolidine 1</PDB_Title>
      <PDB_ID>3G8N</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3G8N</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>3G8O: Rational design of orally-active, pyrrolidine-based progesterone receptor partial agonists.</PubMed_Title>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko04914</Pathway_ID>
      <Pathway_Title>Progesterone-mediated oocyte maturation</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04114</Pathway_ID>
      <Pathway_Title>Oocyte meiosis</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cell growth and death</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>All alpha proteins</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.b.cdh.b.b.j.html</SCOP_URL>
    <CATH_Class>Class 1: Mainly Alpha</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1a28</CATH_URL>
  </Fold>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD00170297</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD00290003</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710060</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD08590001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD08590002</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD08590003</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD08590004</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD08590006</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD08590009</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD08590014</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD08590017</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD08590018</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-06-20</Create_Date>
</Organism_Record>